Symon Cotton has been reflecting on the future of the genomics ecosystem. Here he discusses how genomics – plus the emergence of panomics and long read sequencing – could inform clinical practice and patient care.
The world of DNA testing is changing fast and the race is on to provide cheap, quick genetic diagnoses for patients. Symon Cotton, Head of Life Sciences takes a look at the opportunities on offer for companies working in this dynamic field.
Lizzie Thomas presents her case for designing improved, sustainable drug delivery product design. Currently, the approach is dominated at the outset by patient-centricity. This focus means that wider, more long-term implications simply aren’t considered early enough.
Cell4D is developing ‘fingerprinting’ technology for live cells using mechanomics, a discipline sitting at the intersection of biology and biomechanics. This biomarker that is used to screen and sort live cells for cell therapies.
Global pharma is hitting a major fork in the road, and one way leads to failure. For me, it’s vital that the industry comes together to grasp the once-in-a-generation opportunity that emergent technology is offering.